Citizens cuts Mirum Pharmaceuticals stock price target on valuation
#Mirum Pharmaceuticals #Citizens price target #MIRM stock #Volixibat #Brelovitug #PSC #HDV #Clinical trials
📌 Key Takeaways
- Citizens reduced Mirum Pharmaceuticals' price target from $140 to $132 while maintaining Market Outperform rating
- Mirum has strong commercial momentum with four pivotal clinical readouts expected in the next 18 months
- The stock has surged 115% over the past year but remains unprofitable
- No FDA-approved therapies currently exist for PSC or HDV, representing significant market opportunities
📖 Full Retelling
Citizens lowered its price target on Mirum Pharmaceuticals (NASDAQ:MIRM) shares to $132 from $140 on February 26, 2026, while maintaining a Market Outperform rating on the stock, citing valuation concerns despite the company's strong commercial momentum and upcoming clinical trial readouts. The financial adjustment comes as Mirum Pharmaceuticals enters 2026 with significant momentum, having preannounced preliminary revenues in January and reiterated 2026 revenue guidance of $630 million to $650 million. Citizens highlighted that the company has four pivotal readouts expected over the next 18 months, with the most near-term catalysts being second-quarter readouts from the pivotal Phase 2b VISTAS trial of volixibat for Primary Sclerosing Cholangitis (PSC) and the interim analysis from the Phase 3 AZURE-1 trial of brelovitug for Hepatitis Delta Virus (HDV). The firm assigns volixibat an 80% probability of success in PSC and brelovitug a 60% probability of success. Despite the stock surge of 115% over the past year and trading near its 52-week high of $109.28, Citizens maintains confidence in Mirum's pipeline, modeling peak worldwide sales of approximately $1 billion in PSC and approximately $675 million in HDV. The firm noted that positive VISTAS data will derisk the pivotal Phase 2b VANTAGE readout of volixibat in Primary Biliary Cholangitis (PBC) coming in the first half of 2027. Mirum recently reported strong financial results for the fourth quarter of 2025, with net product sales reaching $149 million, surpassing expectations of $138.89 million and marking a 50.5% increase compared to the same quarter in the previous year. However, the company remains unprofitable with an EPS of -$0.84 over the last twelve months.
🏷️ Themes
Pharmaceutical Development, Financial Markets, Healthcare Investment
📚 Related People & Topics
Volixibat
Chemical compound
Volixibat (INN; development code SHP626) is a medication under development as a possible treatment for nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). No other pharmacotherapy yet exists for NASH, so there is interest in whether volixibat can p...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold just higher ahead of U.S.-Iran nuclear talks Nvidia shares edge up as cash return questions remain despite revenue outlook beat Nvidia, Salesforce earnings; U.S.-Iran nuclear talks - what’s moving markets Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound (South Africa Philippines Nigeria) Citizens cuts Mirum Pharmaceuticals stock price target on valuation By Investing.com Analyst Ratings Published 02/26/2026, 05:36 AM Citizens cuts Mirum Pharmaceuticals stock price target on valuation 0 MIRM 1.06% Investing.com - Citizens lowered its price target on Mirum Pharmaceuticals shares (NASDAQ:MIRM) to $132 from $140 while keeping a Market Outperform rating on the stock. The firm said Mirum enters 2026 with strong commercial momentum and four pivotal readouts expected over the next 18 months. The company preannounced preliminary revenues in January and reiterated 2026 revenue guidance of $630 million to $650 million. Citizens said the most near-term catalysts are second-quarter readouts from the pivotal Phase 2b VISTAS trial of volixibat for PSC and the interim analysis from the Phase 3 AZURE-1 trial of brelovitug for HDV. The firm assigns volixibat an 80% probability of success in PSC and brelovitug a 60% probability of success.The stock has surged 115% over the past year and trades near its 52-week high of $109.28, though InvestingPro analysis suggests shares may be overvalued at current levels. Despite the company’s strong revenue growth of 54% and gross margins near 80%, InvestingPro Tips highlight that Mirum remains unprofitable with an EPS of -$0.84 over the last twelve months. For deeper insights into Mirum’s valuation and growth trajectory, investors can access the comprehensive Pro Research Report available on InvestingPro . No FDA-approved therapies exist for either condition. Citizens models peak worldwide sales of approximately $1 billion in PSC and approximately $675...
Read full article at source